1
TITLE: Influence of HER2 expression on prognosis in metastatic triple-negative breast cancerdresults from an international, multicenter analysis coordinated by the AGMT Study Group
AUTHORS: Gampenrieder, S. P.; Dezentje, V.; Lambertini, M.; de Nonneville, A.; Marhold, M.; Le Du, F.; Salgado, A. Cortes; Costa, D. Alpuim; Batista, M. Vaz; Ruche, N. Chic; Tinchon, C.; Petzer, A.; Blondeaux, E.; Del Mastro, L.; Targato, G.; Bertucci, F.; Goncalves, A.; Viret, F.; Bartsch, R.; Mannsbart, C.; Deleuze, A.; Robert, L.; Serrano, C. Saavedra; Cortes, M. Gion; Sampaio Alves, M.; Vitorino, M.; Pecen, L.; Singer, C.; Harbeck, N.; Rinnerthaler, G.; Greil, R.; ...More
PUBLISHED: 2023, SOURCE: ESMO OPEN, VOLUME: 8, ISSUE: 1
INDEXED IN: WOS
2
TITLE: Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis
AUTHORS: Park, Y. H.; Im, S A.; Ahn, J H.; Kim, M. H.; Cortes, J.; Dent, R. A.; Pusztai, L.; McArthur, H. L.; Kummel, S.; Denkert, C.; O'Shaughnessy, J.; Mouret Reynier, M A.; Ferreira, M. I. R.; Cortes, M. Gion; Boileau, J F.; Hui, R.; Zhu, Y.; Pan, W.; Karantza, V. V.; Schmid, P.;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
INDEXED IN: WOS